6 4

Cited 0 times in

Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study

Authors
 Chul-Won Ha  ;  Yong-Beom Park  ;  Chong-Hyuk Choi  ;  Hee-Soo Kyung  ;  Ju-Hong Lee  ;  Jae Doo Yoo  ;  Ju-Hyung Yoo  ;  Choong-Hyeok Choi  ;  Chang-Wan Kim  ;  Hee-Chun Kim  ;  Kwang-Jun Oh  ;  Seong-Il Bin  ;  Myung Chul Lee 
Citation
 BMC Musculoskeletal Disorders, Vol.18(1) : 223, 2017 
Journal Title
 BMC Musculoskeletal Disorders 
Issue Date
2017
MeSH
Adjuvants, Immunologic/administration & dosage* ; Adjuvants, Immunologic/chemistry ; Aged ; Cross-Linking Reagents/administration & dosage* ; Cross-Linking Reagents/chemistry ; Double-Blind Method ; Female ; Humans ; Hyaluronic Acid/administration & dosage* ; Hyaluronic Acid/chemistry ; Male ; Middle Aged ; Osteoarthritis, Knee/diagnosis* ; Osteoarthritis, Knee/drug therapy* ; Prospective Studies ; Treatment Outcome
Keywords
Hyaluronic acid ; Inflammation ; Knee osteoarthritis ; Treatment
Abstract
BACKGROUND: This randomized, double-blind, multi-center, non-inferiority trial was conducted to assess the efficacy and safety of a cross-linked hyaluronate (XLHA, single injection form) compared with a linear high molecular hyaluronate (HMWHA, thrice injection form) in patients with symptomatic knee osteoarthritis. METHODS: Two hundred eighty seven patients with osteoarthritis (Kellgren-Lawrence grade I to III) were randomized to each group. Three weekly injections were given in both groups but two times of saline injections preceded XLHA injection to maintain double-blindness. Primary endpoint was the change of weight-bearing pain (WBP) at 12 weeks after the last injection. Secondary endpoints included Western Ontario and McMaster Universities Osteoarthritis index; patient's and investigator's global assessment; pain at rest, at night, or in motion; OMERACT-OARSI responder rate; proportion of patients achieving at least 20 mm or 40% decrease in WBP; and rate of rescue medicine use and its total consumption. RESULTS: Mean changes of WBP at 12 weeks after the last injection were -33.3 mm with XLHA and -29.2 mm with HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (-1.9 mm, 10.1 mm) was well above the predefined margin (-10 mm). There were no significant between-group differences in all secondary endpoints. Injection site pain was the most common adverse event and no remarkable safety issue was identified. CONCLUSIONS: This study demonstrated that a single injection of XLHA was non-inferior to three weekly injections of HMWHA in terms of WBP reduction, and supports XLHA as an effective and safe treatment for knee osteoarthritis.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161477
DOI
10.1186/s12891-017-1591-4
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실)
Yonsei Authors
최종혁(Choi, Chong Hyuk)
사서에게 알리기
  feedback
Files in This Item:
T201704912.pdf Download
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse